This story was originally published April 14.

Agilent Technologies said last week that large-scale Chinese genome center BGI will use several of its products as part of its next-generation sequencing process.

Specifically, BGI will use Agilent's SureSelect solution-based target enrichment product for targeted sequencing in human genetic studies, particularly in cancer genome projects.
BGI researchers worked with Agilent's China Life Science group and Agilent R&D to test and validate SureSelect.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.

Researchers examine the gap in funding between researchers and research institutions, ScienceInsider reports